Discontinued — last reported Q1 '26
ProQuad/M-M-R II/Varivax — Sales
Merck & Co. ProQuad/M-M-R II/Varivax — Sales decreased by 56.5% to $538.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.1%, from $1.08B to $538.00M. Over 4 years (FY 2021 to FY 2025), ProQuad/M-M-R II/Varivax — Sales shows an upward trend with a 3.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in sales indicates strong market penetration and consistent demand for routine childhood immunizations, while a decrease may signal increased competition, supply chain constraints, or shifts in public health vaccination policies.
Detailed definition
This metric represents the total annual revenue generated from the sale of a specific portfolio of pediatric vaccines, i...
Peer comparison
Comparable to revenue metrics for specialized pediatric vaccine portfolios or core immunization franchises at other global pharmaceutical companies.
mrk_segment_proquad_m_m_r_ii_varivax_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.03B | $1.32B | $1.02B | $940.00M | $1.16B | $1.34B | $1.05B | $1.06B | $1.16B | $1.43B | $1.09B | $1.14B | $1.23B | $1.41B | $1.19B | $1.08B | $1.22B | $1.37B | $1.24B | $538.00M |
| QoQ Change | — | +28.2% | -23.2% | -7.5% | +22.9% | +15.7% | -21.3% | +0.4% | +10.2% | +22.5% | -23.6% | +4.7% | +8.2% | +13.9% | -15.4% | -9.3% | +13.0% | +12.3% | -9.5% | -56.5% |
| YoY Change | — | — | — | — | +11.9% | +1.0% | +3.5% | +12.3% | +0.8% | +6.7% | +3.6% | +8.0% | +6.0% | -1.4% | +9.1% | -5.5% | -1.3% | -2.7% | +4.1% | -50.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s proquad/m-m-r ii/varivax — sales?
- Merck & Co. (MRK) reported proquad/m-m-r ii/varivax — sales of $538.00M in Q1 2026.
- How has Merck & Co.'s proquad/m-m-r ii/varivax — sales changed year-over-year?
- Merck & Co.'s proquad/m-m-r ii/varivax — sales decreased by 50.1% year-over-year, from $1.08B to $538.00M.
- What is the long-term trend for Merck & Co.'s proquad/m-m-r ii/varivax — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s proquad/m-m-r ii/varivax — sales has grown at a 3.5% compound annual growth rate (CAGR), from $4.27B to $4.90B.
- What does proquad/m-m-r ii/varivax — sales mean?
- Total annual revenue generated from the company's core portfolio of pediatric vaccines.